DWJ1483

DWJ1483 is a long-acting, sustained-release injectable formulation of leuprolide acetate (also known as leuprorelin) being developed by Daewoong Pharmaceutical. It is specifically designed for the treatment of central precocious puberty (CPP), a condition characterized by the premature activation of the hypothalamic-pituitary-gonadal axis. As a gonadotropin-releasing hormone (GnRH) receptor agonist, leuprolide initially stimulates the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). However, continuous administration via a long-acting depot formulation leads to the downregulation and desensitization of GnRH receptors in the pituitary gland. This results in the suppression of gonadotropin secretion and a subsequent reduction in sex steroid levels (testosterone in males and estradiol in females) to prepubertal concentrations, thereby halting the progression of premature sexual development and optimizing final adult height.

Other names

leuprolide acetate long-acting injectableleuprorelin acetate long-acting injectable